Physician profile
Benjamin Garden
NPI 1699193334
$21,857.13
in general payments reported to CMS, 2019-2025
20 companies · $1,582 in 2025
The $1,582 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2020: $107 · 2021: $108 · 2022: $11K · 2023: $8,249 · 2024: $968 · 2025: $1,582.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $7,250 · Food and Beverage: $3,296 · Education: $210 · Travel and Lodging: $44.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $7,250.00 |
| Food and Beverage | $3,295.57 |
| Education | $209.63 |
| Travel and Lodging | $44.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $18,733.72 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $812.59 | 2023-2025 | Tremfya, Simponi, Stelara |
| Genzyme Corporation | $699.38 | 2021-2025 | |
| Abbvie INC. | $605.47 | 2019-2025 | |
| Galderma Laboratories, L.P. | $274.15 | 2019-2025 | Nemluvio, Aklief |
| Regeneron Healthcare Solutions, INC. | $195.82 | 2022-2024 | Dupixent |
| Allergan, INC. | $97.33 | 2019 | |
| Novartis Pharmaceuticals Corporation | $70.00 | 2019-2025 | |
| Mimedx Group, INC. | $48.14 | 2025 | |
| Ucb, INC. | $46.83 | 2025 | Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.14 | 2025 | Spevigo |
| Pfizer INC. | $39.09 | 2020-2025 | |
| Arcutis Biotherapeutics, INC. | $36.36 | 2024-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $28.58 | 2025 | |
| Almirall LLC | $25.93 | 2024 | Klisyri |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $25.79 | 2023 | Vtama |
| Leo Pharma INC. | $21.01 | 2024 | Adbry |
| Incyte Corporation | $20.53 | 2025 | Opzelura |
| Botanix Sb INC | $20.41 | 2025 | Sofdra |
| E.R. Squibb & Sons, L.L.C. | $14.86 | 2024 | Sotyktu |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Garden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.